Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints [A175942]. This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals [A175942]. Allopurinol is a xanthine oxidase enzyme inhibitor that is considered to be one of the most effective drugs used to decrease urate levels and is frequently used in the treatment of chronic gout [A36705]. It was initially approved by the FDA in 1966 [L5674] and is now formulated by several manufacturers [L5677].
Synonyms
4-Hydroxy-3,4-pyrazolopyrimidine
Allopurinol sodium
Allopurinol
4-Hydroxypyrazolyl(3,4-d)pyrimidine
1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidine-4-one
Allopurinolum
4-HPP
4-Hydroxypyrazolo(3,4-d)pyrimidine
Alopurinol
1,5-Dihydro-4H-pyrazolo(3,4-d)pyrimidin-4-one
4-Hydroxy-1H-pyrazolo(3,4-d)pyrimidine
4'-Hydroxypyrazolol(3,4-d)pyrimidine
4-Hydroxypyrazolopyrimidine
4H-Pyrazolo(3,4-d)pyrimidin-4-one
1H-Pyrazolo(3,4-d)pyrimidin-4-ol
Brand Names
PMS-allopurinol
Ag-allopurinol
Jamp Allopurinol Tablets
Novo-purol Tab 100mg
Purinol Tab 300mg
Purinol Tab 100mg
Alloprin
Allopurinol Tablets 100mg
Riva-purinol 200mg Tablets
Duzallo
Ipg-allopurinol
Purinol Tab 200mg
Zyloprim 200
Aloprim
Apo-allopurinol
Nu-allopurinol
Riva-purinol 300mg Tablets
Novo-purol Tab 200 mg
Zyloprim 100
Allopurinol Tablets 300mg
Zyloprim
Allopurinol sodium
Allopurinol Tablets 200mg
Mar-allopurinol
Riva-purinol 100mg Tablets
Allopurinol-200
Novo-purol Tab 300mg
Jamp-allopurinol
Allopurinol-100
Allopurinol
Ntp-allopurinol
Allopurinol-300
Indication
Allopurinol is indicated in [FDA label]: 1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2) the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol should be discontinued when the potential for overproduction of uric acid is no longer present. 3) the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks.
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison
T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS.
Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682
